Maggie Kozman
Research Subjects
Maggie Kozman has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Benjamin Keller
Pediatric Surgery, University of California San Diego, San Diego, California
1 shared publication- Birgit C Schultes
Advanced Immune Therapeutics, Inc, Charlestown, MA, USA
1 shared publication - Christopher F Nicodemus
AIT Strategies, POB 429 Sunset Lane, Franconia, NH 03580, USA
1 shared publication Daniel Hershey
Pediatrics
1 shared publication- Elizabeth Ortiz-Sánchez
Subdirection of Basic Research, National Cancer Institute of Mexico (Instituto Nacional de Cancerología, INCan) 4 , Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, Mexico City 14080
1 shared publication Farhana Ali
Pediatric Gastroenterology
1 shared publication
Latest Publications
- 29 April 2022
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 149 (5)
Hematemesis From Varices in a 14-year-old Without Hepatobiliary Disease: A “Wandering” Diagnosis
- 29 April 2022
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 149 (5)
Hematemesis From Varices in a 14-year-old Without Hepatobiliary Disease: A “Wandering” Diagnosis
- Open Access
- 17 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 195
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa.
- 17 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 195
Open AccessA novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa.